<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 362 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page361.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=362">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 362 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 362</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=362"><img src="../thumb/362.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Immunological - 24.1                                                           2020-04 / 325
       rash, prurit., dry skin, nail,disord., erythema, acne, hand-foot-syndr.,   Special precautions: Liver damage/dis., discont.if infect.develop.  Hepat.reject.prophylax: Oral admin.: Adults: 1,5 g 2xdly.(3 g dly.
       pityrias rosea, arthralg., ren.fail., incr.dayt.urinat., proteinur., ac.ren.  Drug interactions: Eff.enhanc.by allopurinol.  dos.) init.ASAP aft. transplantat. Childr: No data avail.
       fail., irreg. menstruat., amenorrh., fatig., periph.oed., asthen., pyrex.,   For further details refer manufact.prod.lit.  IV admin: 1 g 2xdly.(2 g dly.dos).
                                                                   st
       mucos.inflammat., non-card.chest pain, imp.wound heal., ocul.hy-  1  /refract.ren.reject.: Oral admin/IV: Adults: 1,5 g 2xdly.(3 g dly.
       peraem., decr.weight, URTI, sinusit., otit.med., nasopharyngit., UTI,   AZATHIOPRINE 50 PCH, (Cipla Medpro) Teva [P/S]  dos.). Childr: No data avail.
       pharyngit., cellulit., pneumon., vir.gastoenterit., H.Zoster, vir.bronchit.,   Azathioprine.  Contraindications: Mycophenol.acid./ polysorbate (Tween) hypers-
       aggress., menorrhag., vag.haemorrh., delay.menstruat., ser.hepatit.B   Indications: Part of combin.ther.as immunosuppress. for prev.of   ens., pregn.& lactat., 0,9% normal saline, ringer’s & lactat.ringer’s sol.
       reactivat.incl.fatalit.,      reject.in organ & tiss. transplants, in combinat.with corticoster.in   Side effects: Asthen., fev., headache, infect., abdom./back/chest/
       Warnings and special precautions: Advis.pts. to report new/  auto-immune dis.  pelvic & neck pain, chills, oed., sepsis, ascites, enlarg.abdom., hern.
       worsen.resp.sympts.& consid. diagnos. of.non-infect. interstit.pneu-  (S4) TABS. 37/26/0692.  infect., peritonit., cysts incl.lympho-& hydrocele, fac.oed., flu syndr.,
       monit.& consid. interupt.ther.until sympts improve, ther. may be rein-  712609-001: 50 mg, 100, R627,30  haemorrh., malaise, cellulit., pallor, abscess, bld.dyscras., ecchymos.,
       trod.at grade 1 at a 50% low.dly.dos. than that prev.admin., discont.  Dosage: Indiv.treatm.undertak.on long-term basis unless intol.evid.  incr.prothromb./ thromboplast.time, haematur., ren.tubul.necros., UTI
       at recur.of toxic.to grade 3 or grade 4 non-infect.interstit.pneumonit.   Transplant: Load.dos: Usual.1-5 mg/kg bm/day depend.on   & disords., abnorm.kidn.funct., oligur., albuminur., dysur., hydrone-
       cases, predipos.to infects.esp.with opportunist. pathogens., treat pre-  whether other meds./radiother.admin. concom. Maint.dos.aft.  phros., impot., pyelonephrit., urin.freq./incontin./reten., ac.ren. fail.,
       exist.invas,fung.infect prior to start.treatm., alcoh-/iodine-/thyme-/  transplantat.: Usual.1-4 mg/kg bm/day. Reject.risk poss.aft.dis-  scrot.oed., hyper/hypotens., CV effs., card. fail., pericard.effus., hyper-
                                     cont.even aft.a per.of yrs.
       H 2peroxid.-contain.mouthwash may exagerat.oral.ulcerat.& avoid   cholesterolaem., hyperglycaem., hypo/hyperkalaem., hypophospha-
       antifung.agents unles.fung.infect.diagnos., monit. ren. funct./fast.ser.  Auto-immune dis: Indiv.accord.to sev.& clinic. respons. Usual.  taem., metabol./resp.acidos., metabol. & nutrit.effs., hyperlipaem.,
                                     dos.: 1-2,5 mg/kg bm/day.
       gluc./bld.lipids & complet. bld.count prior to start of ther.& periodic.   hyperuricaem., hypervolaem., hypo/magnesaem./ natraem., weight
       thereaft., monit.clin.resp./undesir.effs.dur. concom. admin.of CYP3A4   Chron.act.hepatit: Init.1-1,5 mg/kg bm/day.  gain/loss, bilirubinaem., hypoproteinaem., hypox., abnorm.heal.,
                                     Contraindications: 6 Mercaptopurine hypersens., pregn., safety
       induc.& inhibit., concom. oral CYP3A4 substrates with narr. therapeut.   gout, GI disturbs./ haemorrh., ileus, oral & GI moniliasis, cholangit.,
       index, sev.hepat.impairm., avoid close contact with those who recent.  in lactat.not est.  cholestat.jaund., hepatit., gingivit., gum hyperplas., oesophagit., sto-
       receiv.live vaccin., pre-surg.period.due to poss.imp.wound heal., est.   Side effects: Fung./protozoal/vir./uncomm.bact. infects., leuco-  matit., mouth ulcerat., rect. disords., stomach ulc., incr.cough, dyspn.,
       eff.on pt.bef.driv/operat.mach., lact intol., avoid grapefruit/grapefruit   pen., anaem., thrombocytopen., macrocytos., neutropen., bone mar-  pharyngit., pneum., bronchit., asthma, pleur.effus., rhinit., sinusit., at-
       juice, bioavail.of oral meds which are CYP3A4 substrat.admin.by non   row aplas., incr. mean corpuscul.vol.& red cell haemoglob.content,   electasis, pulm.oed., apnoea, epistax., haemoptys., hiccough, neo-
       oral routes poss.affect., reproduct.toxic.in anim.stud., passes into   megaloblast. bone marr.chang./sev.megaloblast anaem./ erythoid   plasm, pneumothorax, incr.sputum, voice alterat., hyperventilat.,
       breast milk, male & fem.fertil.poss. comprom., not recom.in paed.  hypoplas., hyperphosphataem., electrol. bal.disturbs., retinopathy,   respir.monilias., acne, H.simplex, /zoster, sweat., skin disords.incl.
       pts.with advanc.ren. cell Ca or TSC with ren.angiomyolipoma in ab-  Raynauds, pulm. oed., pneumonit., GI disturbs.incl.gastric ulcerat./   benign neoplasm, CNS effs., musc.-skelet.effs., vis.disturbs., diab.
       sence of SEGA, not stud./recomm.in paed.SEGA pts.&lt;3 yrs., mild to   intestin.& periton.haemorrh., oral ulcerat., oesophagit., tox.hepatit.,   mellit., parathyroid disord., cush.syndr., hypothyroid., loc.reacts.with
                                     bil.stas., elev.ser.bilirub. lev., hepatit., pancreatit., skin rash, alopec.,
       mod.hepat.impairm., adeq. contracept. dur.treatm.& x8 wks.aft.stop.,   IV admin., vaccin. poss. less effect., ser.life threathen.infects.such
       achiev. optim. glycaem.contr.bef.start.treatm.  skin/ nail pigmentat., arthalg., hyperuricaem., ac.ren. fail., amenorrh.,   as meningit. & infect.endocardit., tuberculos., atypic. mycobacter.
                                     spermatogenes.inhibit., chromosom. abnorm.in recipients themselv.&
       Drug interactions: Vaccinat.poss.less effect., bld conc.incr.by CY-  infect., congenit.disords.
       P3A4/PgP. inhibits. eg. ketoconazol./ itraconazol./fluconazol./vori-  in offspring of transplant recipients where they may disappear in time,   Warnings and special precautions: Incr. lymphomas & other
                                     allerg.reacts., negat.N 2 bal., drug fev., ser.sickn.
       conazol./ ritonav./ clarithromc./telithromyc./erythromyc./ verapam./   malign.partic.of skin develop., teratogen. & mutagen., limit.sun/
       ciclospor./diltiaz./amprenav./ fosamprenav. & aprepitant), CYP3A4/  Special precautions: Consid.benef.-risk, monit. adeq. for tox.  UV light expos., incr. suscept to infect.incl.opportunit./fatal infect.
                                     effs.throughout ther.durat., imp ren. / hepat. funct., avoid.meds.
       PgP induc. decr. bld.conc.(eg.rifampic,/rifabutin/St John’s Wort/   with myelosuppress.eff./ cytostat., if no discern.improvem.evid.  & sepsis, monit.for neutropen.,Fexpe reg.compl. bld. counts wkly.
                                                                              nd
                                                                    st
                                                                                 rd
       carbamazep./phenobarb./phenytoin/ efavirenz & nevirap.), incr.C max   aft.3 mnths. consid. discont., excret.in breast milk, reject.risk aft.   dur.1  month, twice month.2  & 3  month then month.dur.yr., pts.to
       & AUC of concom. oral midazolam                            report any evid. of infect./unexpect.bruis./bleed/bone marr. depress.
                                     ther.discontin., elderly, monit.haematolog. respons., infect.risk.,
       AUBAGIO, Sanofi-Aventis (Pty) Ltd  treat.any arising infects. vigorous., neoplas.vulnerability in trans-  manifestat., avoid live attenuat.vacc.use, act. ser. digest.syst.dis.due
                                                                  to report.GI ulcerat./ haemorrh. & perforat., avoid in rare heredit.def-
       See Section 4.6               plant. organ/ other unrelat.site, compl.bld.counts incl. platel. count   ic.of hypoxanthine-guanine phosphoribosyl-transferase, activ. delay.
                                       st
       AZAMUN, Litha [P/S]           dur.1  8 wks.of ther., poss.discont.in case of haemotopoiet.toxic.,   graft.funct.post-transpl., ren.transpl. with sev.chron.ren.impairm., do
                                     reduc.dos./temporar. withdr. in case of large leucocyte count fall.&/
       Azathioprine.                 other evid.of persist.bone-marr.depress., consid. withhold. in pres.  not admin.with azathioprine., the risk: benef.ratio with tacrolim. not
       Indications: Combin.ther.as immunosuppress.in organ transplants,   of tox.hepatit./bil.statis.  est., meds.that interfer.with enterohepat. recirculat., elderly, phenylke-
       therapeut.eff.in cert.auto-immune dis.when condit.refract.to corticos-  Drug interactions: Eff.enhanc.by allopurinol/ oxipurinol & thio-  tonur.(oral susp. contains phenylalanine), perform.reconstit.& dilut. of
       ter./ when corticoster.dos.produc.sev.side-effs.  purinol, neuromusc.block.of depolaris. agents potent.& block.of   prod. under asept.condits., avoid direct contact of prep. IV sol.with
       (S4) TABS. 36/26/0006         non-polaris. agents reduc., metabol.imp.by furosemide, meds. af-  skin/muc.membr.as teratogen. effs. demonstrat., diarrh./leucopen./
       701252-001: 50 mg, 100, R795,00  fect. leucocyt.product.incl.co-trimoxaz.may exagger. leucopen., sev.  sepsis/infect. & anaem.were more freq.in paed.pts.partic.childr. und.
       Dosage: Do not divide tabs.   leucopen.poss.with ACE inhibit., decr.antibody respon.to vir.vaccin.,   6 yrs., no data avail.for card./hepat.transplant pts. with sev.chron.ren.
       Transplantat: Load.dos: Usual.1-5 mg/kg bm/day. Maint.dos.  potent. of live vir.vacc.replicat.  impairm.or card.transplant. pts. with sev.hepat.parenchym.dis., wom.
       aft.transplantat.: Usual.1-4 mg/kg bm/day. Corticoster.are usual.  of childbear. potent. must have 2 negat.medic.pract./ lab.-supervis.
       giv.concom.                   CELLCEPT, Roche [P/S]        ser./urine pregn.tests with sensitiv. &gt;= 25 mIU/ml & 2nd pregn.test
       Auto-immune dis: Indiv.accord.to sev.& clinic. respons. Usual.  Mycophenolate mofetil  should be perform. 8-10 days aft.1st & 24 hrs.bef init.ther., perf. repeat
       dos.: 1-2,5 mg/kg bm/day.     Indications: Organ reject.prophylax.in allogeneic ren., hepat.& card.  pregn.tests dur.rout.foll.-up visits., use 2 reliable contracept.simultan.
       Act/chron.hepatit: 1-2 mg/kg bm/day  transplants concom.with cyclosporin & corticoster.  bef./dur.& x 90 days. aft.discont.ther., sexual.act.men to use condoms
       Contraindications: 6 Mercaptopurine hypersens., pregn., safety   (S4) CAPS, [P/S] 31/34/0134.  dur. treatm. & x 90 days aft.cessat.of treatm., fem. partn. of male pts.
       in lactat.not est.            833630-008: 250 mg, 100, R2 174,52  recomm.to use effective contracept. dur.treatm. & x90 days aft.ces-
                                                                                            3
       Side effects: Leucopen., thrombocytopen., anaem., pancytopen.,   (S4) ORAL SUSP, [P/S] 35/34/0057  sat., interrupt./ reduc. dos.if absolute neutrophil count is &lt;1,3x10 /µL,
       bleed., bone marrow depress., megaloblast.bone marr.chang./sev.   702819-002: 200 mg/ml, 1, R3 009,41  concom admin.meds.that interf. with enterohepat.recirclat., admin.
       megaloblast anaem./erythoid hypoplas., fung./ protozoal/vir./un-  (S4) IV INFUS, [P/S] 33/34/0201  sevalamer & other Ca free phosph.bind.2 hrs.aft.Cellcept.
       comm.bact.infects., allerg.reacts., alopec., skin reacts., musc./joint   703556-001: 500 mg, 4 vials, R1 153,22  Drug interactions: High.plasma lev.of both meds. when admin.
       pain, fev., rigor., pneumonit., pancreatit., meningit., arrhythm., ren.   (S4) TABS, [P/S] A39/34/0230  tog.with acyclovir., absorpt.decr.with antacids., reduct.of AUC with
       dysfunct., hypotens., anaphylax., CNS effs., GI disturbs. incl.intestin.  707162-001: 500 mg, 50, R2 174,52  cholestyramine, ganciclovir incr.conc.of both meds., drugs known to
       haemorrh.& ulcerat, malaise, weakn., arthalg., liv.funct.impairm.,   Dosage: IV infus.only indic.when oral formulat. not feasib.to be ad-  undergo ren.tubul.secret.may raise plasma conc.of either drug, ri-
       cholestat. jaund., stomatit., mouth ulcerat., negat.N 2 bal., ser. sickn.,   min.within 24 hrs.of. transplantat & for no long.than 5 days. Never   fampic.reduc.mycophenolic acid expos. result.in poss.loss of clinic.
       pulm.oed., periton.haemorrh., retinopathy, Raynauds, hyperuricaem.,   admin. IV sol.by rapid/ bolus inj. Reconstit.to conc. of 6 mg/ml, ad-  effic., norfloxacin & metronidazole reduc.mycophenolic acid AUC,
       ac.ren.fail., hyperphosphataem., skin/nail pigmentat., chromosom.   min.by slow IV infus.over not less than 2 hrs.at approx.infus.rate of   sevalamer decr.mycophenolic acid Cmax & AUC.
       abnorm., poss.suppress.of ovar.& testic. funct.  84 ml/hr. Transf. to oral admin.as soon as able to tol. Do not mix susp.
       Special precautions: Consid.teratogen.potent. in males/females if   with any other meds. Only for use by medic. pract. exper.in immuno-  CERTICAN, Novartis [P/S]
                                                                  Everolimus
       pregn.poss.dur.ther., excret.in breast milk, consid.benef.-risk, monit.  suppress.ther.& managem. of ren./card./hepat.transpl.pts., pts.to be
       adeq.for tox. effs. throughout ther.durat., act.chron.hepatit., imp. ren./  manag.in facilit. equipp.with adeq.lab. & support.medic. resources.  Indications: Reduc.organ reject.risk in adult pts.at low to mod im-
                                                                  munolog.risk receiv.allogeneic ren./ card. transplant combin.with
       hepat.funct.esp.anur.pts., reject.risk.aft. ther. discontin., in auto-im-  Ren.reject.prophylax: Oral admin: Adults: 1,0 g 2xdly. Childr.3
                                                          2
       mune dis.if no discern. improvem. evid.aft.3 mnths.consid.discont.,   mnths-18 yrs: Recomm.oral susp. dos. 600 mg/m  2xdly to max.2 g   ciclospor.for microemuls. & corticoster., prophylax.of ac.organ re-
                                                                  ject.in pts receiv.hepat.transpl.combin.with tacrolimus & corticoster.
       elderly, reduc.maint.dos.to minim.requir.for clinic. respons., monit.  dly. Body surf. area of 1,25-1,5 m : Caps.at dos.750 mg 2xdly. (1,5 g
                                                   2
       haematolog.respons., compl.bld. counts. dur.1  8 wks.of ther., poss.  dly.dos.). Body surf.area of &gt; 1,5 m :1 g 2xdly.  (S4) TABS, 38/37/0686, 0687
                                                   2
                          st
       discont.in case of haemotopoiet. toxic., reduc.dos./withdr.immed.   IV admin: 1 g 2xdly.(2 g dly.dos).  704854-001: 0,25 mg, 60, R1 940,48
       in case of large leucocyte count fall.&/other evid. of persist. bone-  Card.reject.prophylax: Oral admin: Adults: 1,5 g 2xdly (3 g dly.  704892-001: 0,75 mg, 60, R5 821,46
       marr.depress., infect.risk., treat. any arising infects.vigorous., mani-  dos.)start.within 5 days of card. transplant. Childr: No data avail.  Dosage: Admin.only by experic.physic & where whole bld.lev.
                                                                  monit.avail.
       festat.of bone marr. depress.to be report.immed., tox.hepatit., bil.   IV admin: 1,5 g 2xdly.(3 g dly.dos).
       statis, neoplas. vunerability, avoid.meds.with myelosuppress. eff./  Adults: Init.: Gen.kidn.& heart transpl.populat: 0,75 mg 2xdly.soon
                                                                  aft transplant. Hepat.transpl. populat: 1,0 mg 2xdly with init.dos.ap-
       cytostat., concom.warfar.
       Drug interactions: Eff.enhanc.by allopurinol/ oxipurinol & thiopu-  prox.4 wks. aft.transplant.
       rinol, neuromusc.block.of depolaris.agents potent.& block.of non-  The possibility of   Dos.to be giv.consist.eith.with/-out food & at same time as ciclosporin
       polaris. agents reduc., impair.metabol.with furosemide, poss.my-  for micro-emuls./tacrolimus. Bas. on bld lev./tol./indiv.respon.& clin.
       elosuppress.effs.of cimetid.enhanc., meds. affect.leucocyt.product.  drug accumulation   situat. adjust.dos. at 4-5 day.interv.
       incl.co-trimoxaz.may exagger. leucopen., sev.leucopen.poss.with ACE   Ref.to prod.info.for specif.transpl.type dos. recomm.
       inhibit., mercaptopurine reduc.warfar.activ.  should be    Contra-indications: Sirolimus hypersens., pregn. & lactat., he-
                                                                  redit.galact.intol./sev.lact.defic.or gluc.-galact.malabsorpt., con-
       AZAPRESS, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  considered in   com.rifampicin not recomm., avoid grapefruit/grapefruit juice &
       Azathioprine.                                              live vaccinat,
       Indications: Immunosuppress.in transplants.  the presence of   Side-effects: Vir./bact.or fung.infects., sepsis, wound infect., bld.
       (S4) TABS. L/26/413.                significant renal or   dyscras., pericard.effus., hypogonad.in males, hypercholesterolaem.,
       706108-019: 50 mg, 100, R888,39                            hyperlipidaem., hypertriglyceridaem., hypertens., lymphocele., venous
       Dosage: Indiv. 1-5 mg/kg bm dly. Maint.approx. ½ the dose.  hepatic impairment.  thrombo-embol., graft.thrombos., leukocytoclast.vasculit.,  pneumon.,
       Contraindications: Ac.infect., pregn., breast feeding      pleur.effus., interstit.lung dis., pulmon.alveol.proteinos., GI disords.,
       Side effects: Bone marrow depress., tox.hepatit. & pancreatit.,   hepatit., hepat.disords., jaund., abnorm.liv.funct., angioedem., acne,
       musc.wast., skin rash, oral les.                           surg.wound complicat., rash., myalg., UTI, ren.tubul.necros., pyelo-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page361.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>
             </td>
             <td width="35%"><a href="page363.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page363.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
